NCT03378076View on ClinicalTrials.gov

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 6, 2017

Primary Completion Date

March 14, 2018

Study Completion Date

March 14, 2018

Conditions
Bilateral Knee Osteoarthritis
Interventions
DRUG

FX006 32 mg

Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)

DRUG

TAcs 40 mg

Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)

Trial Locations (3)

14609

Rochester Clinical Research, Rochester

16635

Altoona Center for Clinical Research, Duncansville

90509

LA Biomed at Harbor-UCLA Medical Center, Torrance

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY

NCT03378076 - Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA | Biotech Hunter | Biotech Hunter